IN8bio, Inc.

As of June 30, 2026, IN8bio, Inc. carries a market capitalization of 12.31M, placing it among publicly traded companies globally. Its enterprise value stands at -1.50M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

IN8bio, Inc.'s next confirmed earnings release is scheduled for November 5, 2026.

As of June 30, 2026, IN8bio, Inc. has 9.85M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, IN8bio, Inc. maintains a current ratio of 8.21, meaning it holds 8.2x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, IN8bio, Inc. posted a negative return on equity (ROE) of -111.11, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -90.80, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 17.25, a quick read on workforce productivity versus industry peers.

As of the close on October 22, 2026, IN8bio, Inc.'s stock has declined approximately 50.28% over the past 52 weeks. The 50-day moving average sits at 1.03, while the 200-day moving average is 1.29.

Over the twelve months ended June 30, 2026, IN8bio, Inc. generated - - in revenue and converted that into -16.34M in net income, yielding earnings per share of -1.23. EBITDA reached -14.58M, while operating income came in at -16.81M.

As of June 30, 2026, IN8bio, Inc. holds 15.72M in cash and equivalents against 1.91M in total debt, resulting in a net debt position of -15.72M. Total book value stands at 16.07M, with working capital of 14.22M providing operational flexibility.

IN8bio, Inc. produced -12.56M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -211,822.60 in capital expenditures, free cash flow totaled -12.78M - equivalent to -0.96 per share.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -76.80: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -136.76, meaning IN8bio, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

IN8bio, Inc.'s most recent stock split took place on June 6, 2025 with a 30:1 split ratio.

As of June 30, 2026, IN8bio, Inc. has an Altman Z-Score of -9.24, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.